Pipeline

Pipeline

Pipeline

Targeting Adaptive Stress

We have developed a differentiated pipeline of therapy candidates targeting the integrated stress response. We are actively developing our therapeutic candidates in clinical trials for large indications of unmet need for patients.

Our Pipeline


Program
Indication
Line of Therapy

(Monotherapy / Combination)
Preclinical
Phase 1
Phase 2
Phase 3
Program Description HC-7366
(GCN2)
Clear cell renal cell carcinoma (ccRCC)
Post-IO & TKI

(MonoTx)
HC-7366 (monoTx)
Post-IO & TKI

(+ HIF-2α inhibitor)
HC-7366 + HIF-2α
Post-IO

(+ VEGFR TKI)
HC-7366 + VEGFR TKI
Post-IO/IO-naive

(+ immune checkpoint inhibitor)
HC-7366 + ICI
Acute myeloid leukemia (AML)
Relapsed / refractory

(MonoTx)
1L High Risk (iTP53mut)

(+ BCL-2 inhibitor & HMA)

HC-7366, is a differentiated selective, orally bioavailable modulator of a key stress response protein kinase, GCN2.  HC-7366 is under investigation in a Phase 1b trial as monotherapy and in combination with a HIF-2α inhibitor and a VEGFR TKI for the treatment of clear cell renal cell carcinoma.  HC-7366 is also under investigation in a Phase 1b study as monotherapy and in combination with venetoclax and azacitidine for the treatment of acute myeloid leukemia (AML).

Program Description HC-5404
(PERK)
Renal Cell Carcinoma (RCC)
RCC
(VEGFR TKI combo)
HC-5404 + VEGFR TKI

HC-5404, is a differentiated highly selective, orally bioavailable inhibitor of a key stress response protein kinase, PERK.  HC-5404 recently completed investigation in a Phase 1a trial as a monotherapy for the treatment of advanced solid tumors enriched for patients with renal cell carcinoma (RCC) and gastric cancer.  Following the completion of our Phase 1a trial, a Phase 1b trial in combination with a VEGFR TKI is planned.



Targeting the adaptive survival mechanism

Inducing cell-death mechanisms via hyperactivation